Rosen Discusses FDA's Plan to Conduct More Extensive Studies of Generic Blood Pressure Medications
May 6, 2014
Bloomberg
Partner David Rosen was quoted in a Bloomberg article published on May 6, 2014, titled “Blood-Pressure Drug With Thousands of Complaints Draws FDA Test.” The article discussed the U.S. Food and Drug Administration’s plan to conduct more extensive studies of generic blood pressure medications after receiving numerous complaints of ineffectiveness and troublesome side effects. Rosen was quoted saying, “It’s an important issue and we want to make sure these products perform in the way they’re supposed to perform.”
People
Related News
June 10, 2025
In the News
James McFall Joins Iconic Athletes and Leaders in Launch of Stanford Football Alumni United
Foley & Lardner LLP is proud to announce that partner James Carlos McFall is a founding member of Stanford Football Alumni United (SFAU), a newly formed coalition of former players and leaders committed to supporting Stanford Football’s continued growth and national competitiveness.
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."
June 6, 2025
In the News
Louis Lehot Comments on Crypto Company IPO – 'Definitely a home run'
Foley & Lardner LLP partner Louis Lehot commented on the initial public offering of stablecoin issuer Circle in the Law360 article, "Circle's Smash IPO Could Pave Way For More Crypto Listings."